Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2774442 | Endocrinología y Nutrición | 2007 | 10 Pages |
Abstract
Radionucleotide therapy should be used for tumors exhibiting radiotracer uptake, either after surgery to eradicate microscopic residual disease or subsequently if conventional treatment or biotherapy fail. The priority should be to maintain quality of life, particularly because patients with disseminated disease may have prolonged survival.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Concha Sanabria, Natalia Pérez-Ferre, Edurne Lecumberri, Paz De Miguel,